In the third session from the Platelet Reactivity Testing Round Table, the panel discuss treatment options for high-risk PCI patients.
Among the many fascinating points discussed in this session are a number of key issues including (time of discussions within the video are listed in parenthesis):
1:10 – Evidence regarding antiplatelet drug response
3:45 – Treatment options for antiplatelet therapy in the cathlab
8:10 – Interpreting the finding of ARCTIC study
15:14 – Bleeding risk in patients with complex disease
17:40 – Is there a role for platelet function testing in assessing compliance?
18:30 – Value of platelet function testing for assessing whether there is a drug response
22:30 – Is the P2'i'12 assay robust enough to titrate a response?
The panel for this session comprises:
Robert Storey, Professor and Honorary Consultant in Cardiology, Department of Cardiovascular Science, University of Sheffield, UK (Chair)
Jean-Philippe Collet, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
Antonio Colombo, San Raffaele Hospital, Milan, Italy
Jeff Dahlen, Chief Scientific Officer at Accumetrics, US
Radcliffe Cardiology and Interventional Cardiology Review extends its thanks to all panel members.
Platelet Reactivity Testing - Treatment Options for High-risk PCI Patients